CRVS

Corvus Pharmaceuticals, Inc.

CRVS | $1.495 3.82% 90K

(0.0% 1d) (-18.2% 1m) (44.0% 1y) (0.0% 2d) (0.0% 3d) (2.1% 7d) (122.17% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 73,312,680
http://www.corvuspharma.com
Sec Filling | Patents | 53 employees

(US) Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

cancer t-cell cd73 anti-cd3 ceiling

add to watch list Paper trade email alert is off

Press-releases

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
CRVS | $1.495 3.82% 90K

Health Technology

| -11.66% | O: 2.45% H: 0.0% C: -9.58%
dermatitis pharmaceuticals for trial

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-19 (Crawled : 20:00) - globenewswire.com
CRVS | $1.495 3.82% 90K

Health Technology

| -26.53% | O: -2.04% H: 3.06% C: -3.65%
business year update pharmaceuticals results

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
Published: 2024-03-13 (Crawled : 20:00) - globenewswire.com
CRVS | $1.495 3.82% 90K

Health Technology

| -28.0% | O: 0.0% H: 0.5% C: -6.0%
business year update pharmaceuticals financial results

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
Published: 2024-02-12 (Crawled : 13:30) - globenewswire.com
CRVS | $1.495 3.82% 90K

Health Technology

| -34.99% | O: 0.23% H: 5.41% C: 2.25%
pharmaceuticals preclinical

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
CRVS | $1.495 3.82% 90K

Health Technology

| -28.0% | O: 9.0% H: 18.35% C: 1.61%
drug granted cell treatment pharmaceuticals designation

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaCompany on track to initiate soquelitinib Phase 3 registrational clinical trial in PTCL
Published: 2024-02-08 (Crawled : 23:00) - biospace.com/
CRVS | $1.495 3.82% 90K

Health Technology

| -30.43% | O: 0.0% H: 0.0% C: -3.38%
drug granted cell treatment pharmaceuticals designation trial

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
Published: 2024-02-06 (Crawled : 21:00) - globenewswire.com
ABT | News | $108.01 0.88% 1.2M

Health Technology

| -4.29% | O: 2.33% H: 0.0% C: 0.0%
CRVS | $1.495 3.82% 90K

Health Technology

| -29.41% | O: 0.0% H: 2.94% C: 1.47%
business pharmaceuticals

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
Published: 2024-01-23 (Crawled : 22:00) - globenewswire.com
CRVS | $1.495 3.82% 90K

Health Technology

| -29.41% | O: 2.94% H: 0.0% C: -3.33%
pharmaceuticals

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
CRVS | $1.495 3.82% 90K

Health Technology

| Email alert Add to watchlist
cell pharmaceuticals trial

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
Published: 2023-11-02 (Crawled : 13:00) - globenewswire.com
CRVS | $1.495 3.82% 90K

Health Technology

| 22.03% | O: 5.93% H: 5.59% C: -2.4%
cell pharmaceuticals meeting trial

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001610717-24-000106	4	2024-03-01	2024-02-28	Buy	A	400000	400000
0001610717-23-000186	4	2023-06-20	2023-06-15	Buy	A	15000	15000
0001610717-23-000185	4	2023-06-20	2023-06-15	Buy	A	15000	15000